Clinical Trials Logo

Recurrent Glioblastoma clinical trials

View clinical trials related to Recurrent Glioblastoma.

Filter by:

NCT ID: NCT01498328 Completed - Glioblastoma Clinical Trials

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

ReACT
Start date: December 2011
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.

NCT ID: NCT01266031 Completed - Malignant Glioma Clinical Trials

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Start date: July 12, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas. The safety of these drug combinations will also be studied. The goal of this Phase II part of this clinical research study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied.

NCT ID: NCT01251484 Completed - Clinical trials for Recurrent Glioblastoma

BIBF 1120 in Recurrent Glioblastoma Multiforme

Start date: January 2011
Phase: Phase 2
Study type: Interventional

VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM. VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.

NCT ID: NCT00586508 Completed - Clinical trials for Recurrent Glioblastoma

Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

NCT ID: NCT00575146 Completed - Clinical trials for Recurrent Glioblastoma

Ketogenic Diet for Recurrent Glioblastoma

ERGO
Start date: December 2007
Phase: Phase 1
Study type: Interventional

To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma

NCT ID: NCT00503204 Completed - Brain Tumor Clinical Trials

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Start date: September 2007
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

NCT ID: NCT00390299 Completed - Clinical trials for Recurrent Glioblastoma

Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: October 23, 2006
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back. A virus, called MV-CEA, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT00250887 Completed - Clinical trials for Recurrent Glioblastoma

Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy). Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR). EGFR is elevated in more than 50% of malignant gliomas. At recurrence, secondary surgery and pre- and postoperative Gefitinib is offered to patients in good performance status. Clinical outcome of patients and correlation to translational research will be evaluated.